Evidence map›Paper›PMID 38819767›Full record

ReviewDrug delivery and translational research2024

Porous silicon and silica carriers for delivery of peptide therapeutics.

Jiachen Yan, Prakriti Siwakoti, Siuli Shaw, Sudeep Bose, Ganesh Kokil, Tushar Kumeria

Abstract readReview
In one paragraph

Review in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Formation AgI and ZnINanomaterials (Basel, Switzerland) · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiachen Yan *School of Materials Science and Engineering, The University of New South Wales, Sydney, NSW, 2052, Australia.
Prakriti Siwakoti *School of Materials Science and Engineering, The University of New South Wales, Sydney, NSW, 2052, Australia.
Siuli ShawCentre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India.
Sudeep BoseCentre for Medical Biotechnology, Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India.
Ganesh KokilSchool of Materials Science and Engineering, The University of New South Wales, Sydney, NSW, 2052, Australia. g.kokil@unsw.edu.au.
Tushar KumeriaSchool of Materials Science and Engineering, The University of New South Wales, Sydney, NSW, 2052, Australia. t.kumeria@unsw.edu.au.ORCID 0000-0003-3351-7148

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptides have gained tremendous popularity as biological therapeutic agents in recent years due to their favourable specificity, diversity of targets, well-established screening methods, ease of production, and lower cost. However, their poor physiological and storage stability, pharmacokinetics, and fast clearance have limited their clinical translation. Novel nanocarrier-based strategies have shown promise in overcoming these issues. In this direction, porous silicon (pSi) and mesoporous silica nanoparticles (MSNs) have been widely explored as potential carriers for the delivery of peptide therapeutics. These materials possess several advantages, including large surface areas, tunable pore sizes, and adjustable pore architectures, which make them attractive carriers for peptide delivery systems. In this review, we cover pSi and MSNs as drug carriers focusing on their use in peptide delivery. The review provides a brief overview of their fabrication, surface modification, and interesting properties that make them ideal peptide drug carriers. The review provides a systematic account of various studies that have utilised these unique porous carriers for peptide delivery describing significant in vitro and in vivo results. We have also provided a critical comparison of the two carriers in terms of their physicochemical properties and short-term and long-term biocompatibility. Lastly, we have concluded the review with our opinion of this field and identified key areas for future research for clinical translation of pSi and MSN-based peptide therapeutic formulations.

Indexed as

Drug CarriersPeptidesSiliconSilicon DioxideAnimalsDrug Delivery SystemsHumansNanoparticlesPorosityDrug CarriersPeptidesSiliconSilicon DioxideDrug delivery systemsNanocarriersPeptide drugsPeptide encapsulationPorous materials

Identifiers

PMID38819767
PMCPMC11499345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.